Animal models of myasthenia gravis

被引:138
作者
Christadoss, P [1 ]
Poussin, M [1 ]
Deng, CS [1 ]
机构
[1] Univ Texas, Med Branch, Dept Immunol & Microbiol, Galveston, TX 77555 USA
基金
美国国家卫生研究院;
关键词
autoimmunity; myasthenia gravis; pathogenesis; MHC class II; T-cell epitope; cytokines; specific therapy;
D O I
10.1006/clim.1999.4807
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Myasthenia gravis (MG) is an antibody-mediated, autoimmune neuromuscular disease. Animal models of experimental autoimmune myasthenia gravis (EAMG) can be induced in vertebrates by immunization with Torpedo californica acetylcholine receptors (AChR) in complete Freund's adjuvant. The MHC class II genes influence the cellular and humoral immune response to AChR and are involved in the development of clinical EAMG in mice. A dominant epitope within the AChR alpha 146-162 region activates MHC class II-restricted CD4 cells and is involved in the production of pathogenic anti-AChR antibodies by B cells. Neonatal or adult tolerance to this T-cell epitope could prevent EAMG. During an immune response to AChR in vivo, multiple TCR genes are used. The CD28-B7 and CD40L-CD40 interaction is required during the primary immune response to AChR, However, CTLA-4 blockade augmented T- and B-cell immune response to AChR and disease. Cytokines IFN-gamma and IL-12 upregulate, while IFN-alpha downregulates, EAMG pathogenesis, However, the Th2 cytokine IL-4 fails to play a significant role in the development of antibody-mediated EAMG. Systemic or mucosal tolerance to AChR or its dominant peptide(s) has prevented EAMG in an antigen-specific manner. Antigen-specific tolerance and downregulation of pathogenic cytokines could achieve effective therapy of EAMG and probably MG. (C) 2000 Academic Press.
引用
收藏
页码:75 / 87
页数:13
相关论文
共 112 条
[1]   CLINICAL IMPROVEMENT OF MYASTHENIA-GRAVIS BY TREATMENT WITH A CHIMERIC ANTI-CD4 MONOCLONAL-ANTIBODY [J].
AHLBERG, R ;
YI, Q ;
PIRSKANEN, R ;
MATELL, G ;
SWERUP, C ;
RIEBER, P ;
RIETHMULLER, G ;
HOLM, G ;
LEFVERT, AK .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1993, 681 :552-555
[2]   IN-VIVO PREFERENTIAL USAGE OF TCR V-BETA-8 IN TORPEDO ACETYLCHOLINE-RECEPTOR IMMUNE-RESPONSE IN THE MURINE EXPERIMENTAL-MODEL OF MYASTHENIA-GRAVIS [J].
AIMESEMPE, C ;
COHENKAMINSKY, S ;
BRUAND, C ;
KLINGELSCHMITT, I ;
TRUFFAULT, F ;
BERRIH-AKNIN, S .
JOURNAL OF NEUROIMMUNOLOGY, 1995, 58 (02) :191-200
[3]   SERUM GLOBULIN IN MYASTHENIA-GRAVIS - INHIBITION OF ALPHA-BUNGAROTOXIN BINDING TO ACETYLCHOLINE RECEPTORS [J].
ALMON, RR ;
ANDREW, CG ;
APPEL, SH .
SCIENCE, 1974, 186 (4158) :55-57
[4]   RAT INTERFERON ENHANCES THE EXPRESSION OF ACETYLCHOLINE-RECEPTORS IN RAT MYOTUBES IN CULTURE [J].
ANDRE, P ;
BRAUN, S ;
PASSAQUIN, AC ;
COUPIN, G ;
BARTHOLEYNS, J ;
WARTER, JM ;
POINDRON, P .
JOURNAL OF NEUROSCIENCE RESEARCH, 1988, 19 (03) :297-302
[5]  
Andreetta F, 1997, AM J PATHOL, V150, P341
[6]   PREVENTION OF EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS BY MANIPULATION OF THE IMMUNE NETWORK WITH A COMPLEMENTARY PEPTIDE FOR THE ACETYLCHOLINE-RECEPTOR [J].
ARAGA, S ;
LEBOEUF, RD ;
BLALOCK, JE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (18) :8747-8751
[7]  
BAGGI F, MYASTHENIA GRAVIS DI
[8]  
Balasa B, 1998, J IMMUNOL, V161, P2856
[9]   Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune Myasthenia gravis in mice [J].
Balasa, B ;
Deng, CS ;
Lee, J ;
Bradley, LM ;
Dalton, DK ;
Christadoss, P ;
Sarvetnick, N .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (03) :385-391
[10]   Antigen-specific modulation of experimental myasthenia gravis:: Nasal tolerization with recombinant fragments of the human acetylcholine receptor α-subunit [J].
Barchan, D ;
Souroujon, MC ;
Im, SH ;
Antozzi, C ;
Fuchs, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (14) :8086-8091